AUTHORS
Rahul Kumar Thakur, MD, Nisha M. Nair2, Chelsea Peterson, DO3, Alicia Lieberman, MD4, Hillary Jacobson5, Renee McKenzie6, Andrew Ray7, Alex Niu, MD8, Grant Schofield, MD, MSc (MED), FRCPC9, Ehsan Malek, MD10, Maureen Ross, MD, PhD11, Philip L. McCarthy, MD12, Marco Davila, MD, PhD13, Brian C. Betts, MD14, Shernan Holtan, MD15, Megan M Herr, PhD16
AFFILIATIONS
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
3 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
4 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
5 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
6 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
7 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
8 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
9 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
10 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
11 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
12 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
13 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
14 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
15 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
16 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
ABSTRACT
Introduction: Outcomes following allogeneic hematopoietic cell transplantation (allo-HCT) have improved substantially with advances in conditioning regimens, donor selection, supportive care and graft-versus-host disease (GVHD) prophylaxis. As transplantation is increasingly offered to older and medically complex patients, accurately identifying physiologic vulnerability before transplantation has become an important unmet need. Growth differentiation factor-15 (GDF15) is a stress-responsive cytokine released in response to mitochondrial dysfunction, chemotherapy, tissue injury, and systemic inflammation. Through the GFRAL-RET signaling pathway, GDF15 regulates appetite, energy homeostasis, and skeletal muscle metabolism and has emerged as an important mediator of cancer cachexia and physiologic decline. Recent phase II clinical studies demonstrating improvements in appetite, body weight, and lean body mass with GDF15 inhibition establish this pathway as therapeutically actionable.
Objective: Whether pre-transplant circulating GDF15 identifies patients with reduced physiologic reserve and independently predicts outcomes following allo-HCT remains unknown.
Method: Adult patients undergoing allo-HCT between 2018 and 2025 with available prospectively banked pre-conditioning serum were included. Serum GDF15 concentrations were quantified by ELISA, and patients were divided into tertiles based on pre-transplant GDF15 concentrations. Primary endpoints were 1-year overall survival (OS) and progression-free survival (PFS); secondary endpoints included grade II-IV and III-IV acute GVHD (aGVHD), moderate/severe chronic GVHD (cGVHD), relapse, and non-relapse mortality (NRM). OS and PFS were estimated by Kaplan-Meier and compared by log-rank test; competing-risk outcomes were evaluated using cumulative incidence functions and Gray’s test. Multivariable regression evaluated the independent association of GDF15 with 1-year OS and NRM.
Results: A total of 152 patients underwent allo-HCT with available pre-conditioning serum samples. The median age was 61 years (range, 19–81), 58% were aged ≥60 years, and 62% were male. Underlying diagnoses included AML (44%), MDS (20%), and other leukemias (28%); 53% of patients underwent transplantation in complete remission. The majority received reduced intensity/non-myeloablative conditioning (87%), matched unrelated donor transplantation (51%), and peripheral blood stem cell grafts (94%). One-year overall survival was 69%, with infection (38%), disease progression (29%), and GVHD (19%) representing the leading causes of death.
Patients were divided into GDF15 tertiles (<548, 548–1183, and >1184 pg/mL). Higher pre-transplant GDF15 was associated with significantly inferior 1-year OS (≥1184: 51%, 548-1183: 68%, <548: 88%; log-rank P=0.0001) and PFS (≥1184: 47%, 548-1183: 63%, <548: 82%; log-rank P=0.0004) in univariable analyses. On multivariable Cox regression, pre-transplant GDF15 remained independently associated with inferior 1-year OS (overall P=0.02). Compared with GDF15 <548, patients with GDF15 between 548–1183 and >1184 pg/mL had an increased risk of death (HR=2.6, 95% CI, 0.98–6.68; HR=3.7, 95% CI, 1.5–9.2, respectively), after adjusting for donor type and coronary artery disease.
Pre-transplant GDF15 was also independently associated with 1-year NRM (overall P=0.04). Compared with the lowest tertile, the highest two tertiles had a higher 1-year NRM (HR= 4.2, 95%CI, 1.4-13.2; P=0.01), after adjustment for donor type and age. Elevated GDF15 was not associated with chronic GVHD, but it was associated with a higher cumulative incidence of grade II–IV acute GVHD (Gray's test P=0.02). Prespecified age-stratified analyses demonstrated a consistent prognostic association across age groups without evidence of meaningful effect modification.
Conclusions:
Elevated pre-transplant GDF15 independently predicts inferior survival and NRM following allo-HCT and identifies patients with increased biologic vulnerability beyond conventional clinical risk factors. As a stress-responsive cytokine with an emerging therapeutically targetable pathway, GDF15 represents a promising biomarker to refine pre-transplant risk assessment and provides a rationale for prospective studies evaluating biomarker-guided optimization and GDF15-directed therapeutic strategies before allo-HCT.
DISCLOSURES
Rahul Kumar Thakur, MD: No relevant conflicts of interest to declare.